SCHEMBL3405693

SCHEMBL3405693

O=C(Nc1ccc2nc(N[C@@H]3CCc4ccccc43)ccc2c1)Nc1ccccn1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 7/20 0.45
RAB9A P51151 6/20 0.45
MEN1 O00255 3/20 0.45
KMT2A Q03164 3/20 0.45
KDM4E B2RXH2 2/20 0.44
MAPT P10636 3/20 0.44
POLB P06746 1/20 0.44
SMN1; SMN2 Q16637 3/20 0.43
ADORA3 P0DMS8 1/20 0.43
PIM1 P11309 1/20 0.43
ADORA2A P29274 1/20 0.43
ADORA2B P29275 1/20 0.43
ADORA1 P30542 1/20 0.43
FLT3 P36888 1/20 0.43
PIM3 Q86V86 1/20 0.43
AURKB Q96GD4 1/20 0.43
LMNA P02545 3/20 0.43
CYP1A2 P05177 1/20 0.43
CYP2C9 P11712 1/20 0.43
CYP2C19 P33261 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3403165 0.89 KMT2A (0.48) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL3398588 0.87 SMARCA2 (0.46) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL3398554 0.87 NPC1 (0.52) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL3411790 0.86 NPC1 (0.42) NPC1MEN1KMT2AMAPTLMNA
SCHEMBL3405908 0.85 CDK2 (0.45) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL3412407 0.85 JAK2 (0.47) NPC1RAB9AMEN1KMT2AKDM4E
SCHEMBL3401137 0.85 ALDH1A1 (0.43) NPC1MEN1KMT2AKDM4EMAPT
SCHEMBL3401343 0.85 KMT2A (0.56) NPC1RAB9AMEN1KMT2AMAPT
SCHEMBL3414984 0.84 AURKA (0.41) NPC1MEN1KMT2AMAPTHPGDS
SCHEMBL4109902 0.84 MAPT (0.44) NPC1RAB9AMEN1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188284-B2 2-aminoquinolines HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US claimed
US-20090227583-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-09-10 US claimed
US-8188284-B2 2-aminoquinolines HOFFMAN-LA ROCHE INC. (US) 2012-05-29 US disclosed
EP-2252372-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-11-24 EP disclosed
WO-2009109502-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO disclosed
US-20090227583-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG, A SWISS COMPANY (CH) 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227583-A1 2-AMINOQUINOLINES HTR5A, HTR2C, HTR2B NPC1 2445/4885RAB9A 177/4885MEN1 3687/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.